The vice president of the Rare Disease Translational Center at the Jackson Laboratory provided commentary on the next steps needed to further understand stathmin-2’s role as a potential disease-modifying biomarker. [WATCH TIME: 3 minutes]
Cathleen Lutz, PhD
Advertisement
Articles by Cathleen Lutz, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Exploring the Role of Aerobic Exercise in Promoting Remyelination in Multiple Sclerosis: Lindsey Wooliscroft, MD, MS
2
Bilateral MR-Guided Focused Ultrasound Shows Benefit for Managing Parkinson Motor Complications in Phase 3 Trial
3
NLRP3 Inhibitor VTX3232 Well Tolerated, Improves Parkinson Symptoms in Phase 2a Trial
4
Ruptured vs Unruptured Aneurysms: Practical Decision Making with Guilherme Dabus, MD
5
